Ribociclib, sold under the brand name Kisqali, is a medication used for the treatment of certain kinds of breast cancer. Ribociclib is a kinase inhibitor. It was developed by Novartis and Astex Pharmaceuticals.
via Wikipedia infobox
{{Infobox drug | image = Ribociclib skeletal.svg | image_class = skin-invert-image | alt = | caption = | image2 = Ribociclib-from-xtal-3D-bs-17.png | image_class2 = bg-transparent
| pronounce = | tradename = Kisqali | Drugs.com = | MedlinePlus = a617008 | DailyMedID = Ribociclib | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category= | routes_of_administration = By mouth | class = Antineoplastic, CDK inhibitor | ATC_prefix = L01 | ATC_suffix = EF02
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).